08:00 , Dec 20, 2010 |  BioCentury  |  Strategy

TAP's Big Finish

It has taken nearly three decades, but ImmunoGen Inc. is finally getting some traction with its TAP targeted antibody payload platform. The company has closed out 2010 with a rush of news, and now intends...
07:00 , Jun 22, 2009 |  BC Week In Review  |  Clinical News

IMGN242: Development discontinued

ImmunoGen terminated enrollment of a Phase II trial of IMGN242 and discontinued development of the program due to slow progress. The company, which said only a "small portion" of the planned 23 patients in the...
08:00 , Nov 5, 2007 |  BC Week In Review  |  Company News

ImmunoGen, Laureate Pharma Inc. deal

Laureate will manufacture the huC242 antibody for IMGN's huC242-DM4, which delivers DM4 to CanAg-expressing cells. The product is in Phase II testing to treat gastric cancer and CanAg-expressing cancers. ImmunoGen Inc. (IMGN), Cambridge, Mass.  ...
07:00 , Oct 29, 2007 |  BC Week In Review  |  Clinical News

huC242-DM4: Additional Phase I data

Additional data from a Phase I trial showed that the MTD of huC242-DM4 was 168 mg/m 2 given every 3 weeks. At a higher dose (223 mg/m 2), there were 2 cases of reduced visual...
07:00 , Aug 6, 2007 |  BC Week In Review  |  Clinical News

huC242-DM4: Phase II started

IMGN started a U.S. Phase II trial of 168 mg/m 2 of huC242-DM4 given once every 3 weeks in about 40 patients with metastatic or locally advanced gastric or gastroesophageal cancer who have failed front-line...
07:00 , Jun 11, 2007 |  BC Week In Review  |  Clinical News

huC242-DM4: Phase I data

In a dose-escalation Phase I trial in 30 patients with CanAg-expressing solid tumors, the MTD of huC242-DM4 has not been reached. There was no toxicity at doses up to and including 168 mg/m 2 given...
08:00 , Nov 13, 2006 |  BC Week In Review  |  Clinical News

huC242-DM4: Phase II start

IMGN will start a Phase II trial in mid-2007. ImmunoGen Inc. (IMGN), Cambridge, Mass.   Product: huC242-DM4   Business: Cancer   Molecular target: NA   Description: HuC242 antibody which binds to DM4 to CanAg  ...
08:00 , Nov 13, 2006 |  BC Week In Review  |  Clinical News

huC242-DM4: Interim Phase I data

Interim data from a dose-escalation Phase I trial showed that the half-life of huC242-DM4 was 5 days in patients with low levels of CanAg antigen. About 28 patients have received at least 1 dose of...
07:00 , Jun 12, 2006 |  BC Week In Review  |  Company News

CanAg Diagnostics AB, Fujirebio Diagnostics Inc. deal

Fujirebio acquired CanAg for an undisclosed sum. Both companies focus on cancer tests based on serum tumor markers. CanAg Diagnostics AB , Gothenburg, Sweden   Fujirebio Diagnostics Inc. , Tokyo, Japan   Business: Diagnostic  ...
07:00 , Oct 10, 2005 |  BioCentury  |  Tools & Techniques

The ADC space

The ADC space The ADC space Selected companies with antibody-toxin immunoconjugates in preclinical and/or clinical development. (A) Subsidiary of CryoLife (CRY) formed in 2001; (B) Auristatin E is a small peptide; (C) Joint venture between...